🦟 Yellow Fever Vaccine Tracker Dashboard
Tracking the highly effective 17D live-attenuated yellow fever vaccine and next-generation candidates. Yellow fever causes ~30,000 deaths annually in endemic African and South American regions. The 17D vaccine (Stamaril, YF-Vax) provides >95% protection for 10+ years after a single dose. This tracker monitors the licensed 17D vaccine and emerging improved formulations.
Yellow Fever Vaccines by Development Phase
✅ Licensed Yellow Fever Vaccine
Technology
Live-attenuated virus (17D strain)
Efficacy
>95% protection
Duration
10+ years (single dose)
WHO Prequalified
Yes
Details: The 17D yellow fever vaccine is one of the safest and most effective vaccines ever developed. Derived from a wild-type yellow fever virus strain attenuated through serial passage in embryonic tissue, it provides long-lasting immunity after a single dose. The vaccine is required for travel to endemic regions in Africa and South America. Rare serious adverse events include viscerotropic disease and neurotropic disease (~1 per 200,000-300,000 doses), primarily in elderly and immunocompromised individuals.
Current Status: Widely available in endemic regions and for international travelers. WHO recommends routine immunization in endemic countries and for travelers to affected areas. The vaccine has been in use since 1937 with an excellent safety profile.
🔬 Phase 2 Clinical Trials
Developer
Biofarma Indonesia
Technology
Modified live-attenuated
Target
Improved safety profile
Status
Phase 2 ongoing
Description: Modified version of the 17D strain designed to reduce the already rare serious adverse events. Focus on improving safety for elderly populations and immunocompromised individuals who have higher risk of viscerotropic and neurotropic complications.
🧪 Phase 1 Clinical Trials
Technology
DNA plasmid vaccine
Target
Safer alternative to live vaccine
Advantage
No live virus replication
Description: DNA-based vaccine encoding yellow fever virus envelope proteins. Eliminates risks associated with live-attenuated vaccines while maintaining immunogenicity. Early Phase 1 trials assessing safety and immune response.
Technology
Replication-deficient adenovirus
Target
Immunocompromised populations
Status
Early Phase 1
Description: Adenovirus vector expressing yellow fever virus antigens. Designed for safer use in immunocompromised individuals who cannot receive live-attenuated vaccines.
🔬 Preclinical Development
Description: mRNA-based vaccine encoding yellow fever virus structural proteins. Leveraging mRNA platform success from COVID-19 vaccines. Animal studies show promising immunogenicity. Could offer advantages in manufacturing speed and scalability for outbreak response.
Description: Virus-like particles (VLPs) presenting yellow fever envelope proteins. Mimics virus structure without genetic material. Preclinical studies in non-human primates show strong neutralizing antibody responses.
Description: Recombinant yellow fever envelope (E) protein with adjuvant. Early animal studies demonstrate protective immunity. Could provide safer alternative for populations at higher risk from live vaccines.